Last reviewed · How we verify
STSA-1301 subcutaneous injection
At a glance
| Generic name | STSA-1301 subcutaneous injection |
|---|---|
| Sponsor | Jiangsu BioJeTay Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) (PHASE1, PHASE2)
- The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |